Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/... Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. Mehr anzeigen
PDUFA target action date is June 30, 2025 If approved, avutometinib in combination with defactinib would be the first-ever FDA-approved treatment specifically for adults with recurrent KRAS...
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc...
No dose-limiting toxicities were observed in the RAMP 203 first triplet combination cohort of avutometinib and LUMAKRAS™ (sotorasib) plus defactinib in patients previously treated with a G12C...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.575 | 66.5374677003 | 3.87 | 6.78 | 3.455 | 5402627 | 4.75132118 | CS |
| 4 | 0.985 | 18.0402930403 | 5.46 | 6.78 | 3.455 | 1751795 | 4.73149961 | CS |
| 12 | 3.505 | 119.217687075 | 2.94 | 6.78 | 2.54 | 1374870 | 4.24825932 | CS |
| 26 | 3.255 | 102.037617555 | 3.19 | 6.78 | 2.1 | 927927 | 3.75039687 | CS |
| 52 | -1.695 | -20.8230958231 | 8.14 | 14.22 | 2.1 | 700383 | 4.37315558 | CS |
| 156 | -18.155 | -73.8008130081 | 24.6 | 25.56 | 2.1 | 1119572 | 10.75911269 | CS |
| 260 | -9.875 | -60.5085784314 | 16.32 | 59.22 | 2.1 | 2068895 | 21.75100697 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
